Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate Cancer

Posted by Rana R. McKay, MD | Dec 2020

Rana R. McKay, MD, presented “Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate Cancer” for the Grand Rounds in Urology audience in December 2020.

How to cite: McKay, Rana R. “Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate Cancer” December 2020. Accessed Apr 2024. https://dev.grandroundsinurology.com/overall-survival-with-sipuleucel-t-in-patients-treated-for-advanced-prostate-cancer/

Summary:

Rana R. McKay, MD, Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center, discusses the results of a real-world analysis examining survival outcomes in Medicare beneficiaries with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with sipuleucel-T and more recently-approved novel hormonal agents in a real-world treatment setting. Dr. McKay explains that findings show that, for the population studied, use of sipuleucel-T and oral agent results in a statistically significant improvement in overall survival and reduction in mortality compared to patients who never received sipuleucel-T, regardless of when it was given. Following her presentation, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, conducts a Q&A session with Dr. McKay in which they discuss the increasing acceptance of sipuleucel-T among medical oncologists, how complementary MOAs may improve patient outcomes, and the future of sipuleucel-T, among other clinical topics.

About The Author

Rana R. McKay, MD

Rana R. McKay, MD, is an Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center. She is a board-certified medical oncologist who specializes in treating people with urogenital cancers, including bladder, kidney, prostate, and testicular cancer. Her research interests include the design and implementation of clinical trials to advance the treatment of patients with urologic cancers. She serves as the Principal Investigator of several early phase trials in kidney and prostate cancer. As a clinical investigator, she is committed to advancements that will improve the lives of individuals with cancer. Furthermore, she is interested in understanding mechanisms of response and resistance to specific cancer therapies. Her work has appeared in peer- reviewed publications such as Nature, The Lancet, The Journal of Clinical Oncology, Clinical Cancer Research, Cancer, among others. Dr. McKay earned her medical degree at the University of Florida College of Medicine before completing her residency in Internal Medicine at Johns Hopkins Hospital. She also completed a fellowship in Oncology/Hematology at the Dana-Farber Cancer Institute of Harvard Medical School. She went on to serve as an Assistant Professor at Harvard Medical School and a medical oncologist at Dana-Farber/Brigham and Women’s Cancer Center in Boston before joining UC San Diego Health.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Exercise & Wellness

Share This